2,321 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Zega Financial LLC

Zega Financial LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,321 shares of the company’s stock, valued at approximately $2,101,000. Eli Lilly and Company accounts for about 0.4% of Zega Financial LLC’s holdings, making the stock its 20th biggest position.

A number of other hedge funds have also recently modified their holdings of the business. AMJ Financial Wealth Management bought a new position in Eli Lilly and Company during the 4th quarter valued at approximately $201,000. Aveo Capital Partners LLC boosted its holdings in Eli Lilly and Company by 8.2% in the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after acquiring an additional 153 shares in the last quarter. Gryphon Financial Partners LLC grew its stake in shares of Eli Lilly and Company by 19.4% in the fourth quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after acquiring an additional 377 shares during the last quarter. Hillsdale Investment Management Inc. increased its holdings in shares of Eli Lilly and Company by 11.0% during the fourth quarter. Hillsdale Investment Management Inc. now owns 804 shares of the company’s stock valued at $469,000 after acquiring an additional 80 shares in the last quarter. Finally, Sachetta LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth about $99,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on LLY shares. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Bank of America raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $977.35.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 17,229 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the completion of the transaction, the insider now directly owns 97,556,910 shares in the company, valued at approximately $88,033,404,445.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 451,900 shares of company stock valued at $418,732,178 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 1.9 %

Shares of LLY stock opened at $906.17 on Wednesday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53. The stock has a market cap of $861.23 billion, a P/E ratio of 133.46, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a 50 day simple moving average of $896.70 and a two-hundred day simple moving average of $835.96.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. On average, research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.